BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely
to affect its natural history. We tested the hypothesis that simulataneous targeting of the
epidermal growth factor receptor (EGFR) and insulin‐like growth factor receptor–1 (IGF‐1R)
pathways would significantly improve progression‐free survival (PFS) by abrogating
reciprocal signaling that promote drug resistance METHODS This was a phase Ib/II study
testing cixutumumab, combined with erlotinib and gemcitabine (G) in patients with untreated …

4019 Background: Targeting a single pathway in pancreatic adenocarcinoma (PAC) is
unlikely to impact its natural history. EGFR targeting with erlotinib added to gemcitabine (G)
marginally improved the outcome of patients with advanced disease. We tested the
hypothesis that if the EGFR and IGF-1R pathways are simultaneously blocked then
progression free survival (PFS) would be significantly improved by abrogating reciprocal
signaling that leads to resistance to either drug. Methods: This was a phase I/randomized …